PENN AVENUE PARTNERS

Lobbying for ALKERMES, INC. · Pharmaceutical manufacturing and biopharmaceutical company.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · Massachusetts · House · Senate · $70,000.00 income · posted Jul 9, 2025

Bills named in this filing 1

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 1

Pharmacy

Regulatory and legislative issues impacting Alkermes. Appropriations. H.R.1 - One Big Beautiful Bill Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.